REPRISE III, the largest randomized, head-to-head comparison of two transcatheter valves, has reassured Boston Scientific Corp. that its Lotus repositionable, mechanically expanded transcatheter aortic valve will be able to compete with the more established TAVR systems once it reaches the market.
Ted E. Feldman of the NorthShore University HealthSystem in Evanston, Illinois presented one-year results from the global, multi-center trial at the the EuroPCR Scientific Program in Paris on May 16
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?